Skip to main content


Cardiovascular Diabetology’s anniversary collection

New Content ItemFifteen years ago, professors Alexander Tenenbaum and Enrique Fisman conceived the idea of creating a scientific journal specifically dedicated to exploring the intersection of diabetes and heart disease. Following their initiative, the journal Cardiovascular Diabetology was launched in April 2002.

Since then, Cardiovascular Diabetology has been growing rapidly, and fortunately became a prestigious international journal that has published more than 1250 scientific articles - some of them representing a major breakthrough in their particular fields. The journal is privileged to have a high-status Editorial Board, a rigorous peer review policy, a multidisciplinary audience, high visibility, and ample global exposure.

April 2002 may also be considered as the official "birthday" of a novel medical area - cardiovascular diabetology - a discipline specifically dedicated to fight against cardio-diabetes and metabolism-related cardiovascular diseases.  On this occasion, Cardiovascular Diabetology would like to express its gratitude to the worldwide recognized scientists on its Editorial Board, the authors, the publisher’s staff, the reviewers and the readership for their continuous backing and assistance.

We are pleased to present the most influential manuscripts in cardiovascular diabetology published over our 15 year history and we look forward to the prolific studies the next 15 years will bring. We believe that the rapid progress of cardiovascular diabetology will lead to even more impressive achievements in both basic and clinical science, which will be reflected in improved public health.

The future looks encouraging.

  1. Content type: Original investigation

    Circulating microRNAs (miRs) are differentially regulated and selectively packaged into microparticles (MPs). We evaluated whether diabetes mellitus alters circulating vascular and endothelial MP-incorporated ...

    Authors: Felix Jansen, Han Wang, David Przybilla, Bernardo S. Franklin, Andreas Dolf, Philipp Pfeifer, Theresa Schmitz, Anna Flender, Elmar Endl, Georg Nickenig and Nikos Werner

    Citation: Cardiovascular Diabetology 2016 15:49

    Published on:

  2. Content type: Original investigation

    A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase 2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of dapagliflozin. This showed no increase in CV risk w...

    Authors: Christian Sonesson, Peter A. Johansson, Eva Johnsson and Ingrid Gause-Nilsson

    Citation: Cardiovascular Diabetology 2016 15:37

    Published on:

  3. Content type: Original investigation

    Overweight or obesity contributes to the development of type 2 diabetes mellitus (T2DM) and increases cardiovascular risk. Exenatide, a glucagon-like peptide-1 receptor agonist, significantly reduces glycated ...

    Authors: Lawrence Blonde, Richard Pencek and Leigh MacConell

    Citation: Cardiovascular Diabetology 2015 14:12

    Published on:

  4. Content type: Original investigation

    This study evaluated the effect of empagliflozin on postprandial glucose (PPG) and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus (T2DM).

    Authors: Rimei Nishimura, Yuko Tanaka, Kazuki Koiwai, Kohei Inoue, Thomas Hach, Afshin Salsali, Søren S Lund and Uli C Broedl

    Citation: Cardiovascular Diabetology 2015 14:11

    Published on:

  5. Content type: Original investigation

    Diabetes increases the risk of heart failure but the underlying mechanisms leading to diabetic cardiomyopathy are poorly understood. Left ventricle diastolic dysfunction (LVDD) is one of the earliest cardiac c...

    Authors: Ricardo Fontes-Carvalho, Ricardo Ladeiras-Lopes, Paulo Bettencourt, Adelino Leite-Moreira and Ana Azevedo

    Citation: Cardiovascular Diabetology 2015 14:4

    Published on:

  6. Content type: Original investigation

    It has been reported that increased expression of UCP-2 in the vasculature may prevent the development of atherosclerosis in patients with increased production of reactive oxygen species, as in the diabetes, o...

    Authors: Almudena Gómez-Hernández, Liliana Perdomo, Natalia de las Heras, Nuria Beneit, Óscar Escribano, Yolanda F Otero, Carlos Guillén, Sabela Díaz-Castroverde, Beatriz Gozalbo-López, Victoria Cachofeiro, Vicente Lahera and Manuel Benito

    Citation: Cardiovascular Diabetology 2014 13:108

    Published on:

  7. Content type: Study protocol

    Evidence concerning the importance of glucose lowering in the prevention of cardiovascular (CV) outcomes remains controversial. Given the multi-faceted pathogenesis of atherosclerosis in diabetes, it is likely...

    Authors: Bernard Zinman, Silvio E Inzucchi, John M Lachin, Christoph Wanner, Roberto Ferrari, David Fitchett, Erich Bluhmki, Stefan Hantel, Joan Kempthorne-Rawson, Jennifer Newman, Odd Erik Johansen, Hans-Juergen Woerle and Uli C Broedl

    Citation: Cardiovascular Diabetology 2014 13:102

    Published on:

  8. Content type: Original investigation

    Rat neonate cardiomyocytes were cultured and treated with AGEs at different concentration. Two classic autophagy markers, microtubule-associated protein 1 light chain 3 (LC3) and Beclin-1, were detected by wes...

    Authors: Xuwei Hou, Zhaohui Hu, Hanying Xu, Jian Xu, Shunrong Zhang, Yigang Zhong, Xiuying He and Ningfu Wang

    Citation: Cardiovascular Diabetology 2014 13:78

    Published on:

  9. Content type: Original investigation

    Individuals with type 1 diabetes mellitus are at high risk for the development of hypertension, contributing to cardiovascular complications. Hyperglycaemia-mediated neurohormonal activation increases arterial...

    Authors: David ZI Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten and Uli C Broedl

    Citation: Cardiovascular Diabetology 2014 13:28

    Published on:

  10. Content type: Original investigation

    Advanced glycation end products (AGEs) and receptor RAGE interaction play a role in diabetic vascular complications. Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potential therapeutic target for type 2 di...

    Authors: Yuji Ishibashi, Takanori Matsui, Sayaka Maeda, Yuichiro Higashimoto and Sho-ichi Yamagishi

    Citation: Cardiovascular Diabetology 2013 12:125

    Published on:

  11. Content type: Original investigation

    This study investigated the cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin versus comparator treatments.

    Authors: Odd Erik Johansen, Dietmar Neubacher, Maximilian von Eynatten, Sanjay Patel and Hans-Juergen Woerle

    Citation: Cardiovascular Diabetology 2012 11:3

    Published on:

  12. Content type: Original investigation

    It is important for patients that treatments for diabetes not increase cardiovascular (CV) risk. The objective of this analysis was to examine retrospectively the CV safety of exenatide BID, a GLP-1 receptor a...

    Authors: Robert Ratner, Jenny Han, Dawn Nicewarner, Irina Yushmanova, Byron J Hoogwerf and Larry Shen

    Citation: Cardiovascular Diabetology 2011 10:22

    Published on:

  13. Content type: Original investigation

    Our aim was to compare the effects of a Paleolithic ('Old Stone Age') diet and a diabetes diet as generally recommended on risk factors for cardiovascular disease in patients with type 2 diabetes not treated w...

    Authors: Tommy Jönsson, Yvonne Granfeldt, Bo Ahrén, Ulla-Carin Branell, Gunvor Pålsson, Anita Hansson, Margareta Söderström and Staffan Lindeberg

    Citation: Cardiovascular Diabetology 2009 8:35

    Published on:

  14. Content type: Review

    The endothelium is a thin monocelular layer that covers all the inner surface of the blood vessels, separating the circulating blood from the tissues. It is not an inactive organ, quite the opposite. It works ...

    Authors: Ricardo J Esper, Roberto A Nordaby, Jorge O Vilariño, Antonio Paragano, José L Cacharrón and Rogelio A Machado

    Citation: Cardiovascular Diabetology 2006 5:4

    Published on:

  15. Content type: Original investigation

    Inflammation contributes to cardiovascular disease and is exacerbated with increased adiposity, particularly omental adiposity; however, the role of epicardial fat is poorly understood.

    Authors: Adam R Baker, Nancy F da Silva, David W Quinn, Alison L Harte, Domenico Pagano, Robert S Bonser, Sudhesh Kumar and Philip G McTernan

    Citation: Cardiovascular Diabetology 2006 5:1

    Published on:

  16. Content type: Review

    There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high density lipoprotein (...

    Authors: Alexander Tenenbaum, Michael Motro and Enrique Z Fisman

    Citation: Cardiovascular Diabetology 2005 4:14

    Published on:

  17. Content type: Review

    Cardiovascular complications, characterized by endothelial dysfunction and accelerated atherosclerosis, are the leading cause of morbidity and mortality associated with diabetes. There is growing evidence that...

    Authors: Jeanette Schultz Johansen, Alex K Harris, David J Rychly and Adviye Ergul

    Citation: Cardiovascular Diabetology 2005 4:5

    Published on: